drugset / Trial / NCT00228605

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

NCT00228605

Phase 3 Completed 500 enrolled Cephalon
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.

Timeline

Start
2005-03
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified